Top Industry News
- FDA Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry
- India Publishes Changes to Drug Pricing Legislation, Moves to Update Multiple Forms
- FDA Assessing User Fees Under the Generic Drug User Fee Amendments of 2022
- Philippine FDA Seeks Feedback on Plans to Automate License to Operate Application System
- ANVISA Receives Visit from Representatives of the South African Regulatory Agency
- ECHA Registration, Evaluation, Authorization and Restriction of Chemicals
- FDA Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry
- New Guidance on Completing a Pre-Introduction Report: Internationally Assessed for the Environment Only
- TGA Supports MHRA’s New International Recognition Framework for Medicines
- FDA update guidance on E6(R3) Good Clinical Practice (GCP)
- Trade Groups Join Forces to Push Back Against EU health Data Opt-Out, Citing ‘Real Risk’ of Bias